Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | MVD | P53602 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000948 | 1.00 | ACE (0.53) | ACEMEN1ALDH1A1TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL10976646 | 0.99 | ACE (0.52) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL7264251 | 0.95 | ACE (0.49) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL8352289 | 0.89 | MEN1 (0.49) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL14979025 | 0.89 | MEN1 (0.49) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL2744394 | 0.88 | MEN1 (0.48) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL6468703 | 0.88 | KLK5 (0.53) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3763934 | 0.88 | MEN1 (0.48) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL14235217 | 0.88 | KLK5 (0.53) | ACEMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL21101551 | 0.87 | MEN1 (0.47) | ACEMEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3735297-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | Cybrexa 1, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2019136298-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | Cybrexa, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019136298-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | Cybrexa, Inc. (US) | 2019-07-11 | — | — | WO | disclosed |
| US-20190209580-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-2513113-B1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-6207160-B1 | POLYPEPTIDES | LA JOLLA PHARMACEUTICAL COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-0954531-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | Lajolla Pharmaceutical Company (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0833648-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | JOLLA PHARMA (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0954531-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1999-08-31 | — | — | EP | disclosed |
| US-5852051-A | Dipeptide p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl radicals | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| EP-0833648-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040197-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1997-04-24 | — | — | WO | disclosed |
| WO-1996040197-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | ACE 342/4885MEN1 1137/4885ALDH1A1 351/4885 |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | ACE 153/4885MEN1 4112/4885ALDH1A1 2541/4885 |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, VHL | ACE 342/4885MEN1 1137/4885ALDH1A1 351/4885 |
| US-12427157-B2 | Methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, EGLN3 | ACE 455/4885MEN1 1798/4885ALDH1A1 355/4885 |
| US-20190209580-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | ACE 342/4885MEN1 1137/4885ALDH1A1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.